VIVA BIOTECH (01873) surged over 13% again, with cumulative monthly gains exceeding 40%. As of press time, the stock rose 13.21% to HK$2.4, with trading volume of HK$50.34 million.

On the news front, XtalPi Holdings recently reached a cooperation agreement with DoveTree, setting a new record for AI drug discovery collaboration orders. Shanxi Securities noted that the continuous emergence of large-scale collaboration orders between AI pharmaceutical companies and multinational corporations validates the feasibility of AI pharmaceutical companies achieving profitability through technology licensing and revenue-sharing models, and demonstrates the urgent demand from traditional pharmaceutical giants for AI-assisted drug development.

Guoyuan International pointed out that VIVA BIOTECH began its AI pharmaceutical layout five years ago, with AI-related orders now accounting for 12% of new contract signings and showing a growing trend. The company's AIDD and CADD platforms possess capabilities for proprietary algorithm development and platform construction, have experience in developing various drug forms, and fully leverage Viva's structure-based drug development advantages.

Building on this foundation, Viva is transitioning from a stage primarily focused on empowering various drug development phases through computational methods to a new stage of AI-driven drug design that transforms drug design paradigms.